R1 RCM Inc. (NASDAQ:RCM) Shares Sold by Capital International Investors

Capital International Investors lessened its holdings in shares of R1 RCM Inc. (NASDAQ:RCM) by 78.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,821,669 shares of the healthcare provider’s stock after selling 6,521,530 shares during the period. Capital International Investors owned approximately 0.43% of R1 RCM worth $23,463,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new stake in R1 RCM during the first quarter worth about $27,000. ANTIPODES PARTNERS Ltd lifted its holdings in shares of R1 RCM by 429.5% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock worth $59,000 after purchasing an additional 4,561 shares during the last quarter. Van ECK Associates Corp increased its position in R1 RCM by 20.5% in the 4th quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock valued at $65,000 after acquiring an additional 1,044 shares during the period. QRG Capital Management Inc. acquired a new position in shares of R1 RCM during the 1st quarter valued at $132,000. Finally, Covestor Ltd increased its position in shares of R1 RCM by 340.9% during the 1st quarter. Covestor Ltd now owns 13,438 shares of the healthcare provider’s stock valued at $172,000 after purchasing an additional 10,390 shares during the period. Institutional investors and hedge funds own 61.10% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on RCM shares. Royal Bank of Canada restated an “outperform” rating and issued a $19.00 target price on shares of R1 RCM in a research note on Friday, June 28th. Robert W. Baird reaffirmed an “outperform” rating and issued a $18.00 price target on shares of R1 RCM in a report on Tuesday, July 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of R1 RCM in a research note on Monday. Truist Financial restated a “hold” rating and set a $16.00 price target on shares of R1 RCM in a research report on Monday, April 1st. Finally, KeyCorp reissued a “sector weight” rating on shares of R1 RCM in a research note on Wednesday, April 10th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

R1 RCM Stock Performance

NASDAQ RCM traded up $0.09 during trading hours on Friday, hitting $13.01. 1,707,017 shares of the company’s stock traded hands, compared to its average volume of 3,110,600. The business’s fifty day moving average price is $12.55 and its two-hundred day moving average price is $12.16. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $5.48 billion, a P/E ratio of -162.56 and a beta of 0.85. R1 RCM Inc. has a 52 week low of $8.87 and a 52 week high of $18.53.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The business had revenue of $603.90 million for the quarter, compared to the consensus estimate of $612.88 million. R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. Equities research analysts predict that R1 RCM Inc. will post -0.2 EPS for the current year.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.